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Key points:
• Previous research shows
patients have unrealistic
expectations of preventive
medication and that many
default long-term
• Informed choice requires
that patients understand the
balance of benefit against
the risk, but imparting such
information is difficult
• The focus groups showed
the majority of participants
had received very little or no
information on the benefits
or disadvantages
• Younger patients were
receptive to being involved
in decision-making, others
trusted the doctor to
recommend appropriate
medication
• The preferred format is
written text or graphics
giving information specific to
the individual
Abstract
Background: Patients may have unrealistic expectations of preventive treatment and frequently do not take long-term medication.
Involvement of the patient in the decision to start such medication may improve this, but enabling an informed decision is notoriously
difficult.
Aims: To explore patients’ perceptions of preventive medication, the desire for informed choice and how this could best be achieved.
Method: Purposive sampling was used to select patients registered with one of two general practices in South England. Audio
recording, transcription and computer-assisted textual analysis were conducted for focus group discussions.
Results: This was a small study, but the majority of focus group participants who had been prescribed a preventive medication said
they received very little or no information about benefits and disadvantages when it was started. Some felt that doctors did not want to
share information. Older participants thought that choice was over-rated, trusted their doctor to recommend appropriate medication and
did not necessarily wish to be involved in the decision. Younger participants wanted to be more involved. However, even those who
expressed little interest in involvement felt that personalised information compared with population norms comparing individuals to the
‘average person’ would be helpful. Written information specific to the individual and on how the medication or lifestyle changes might
affect them was considered welcome.
Conclusions: Doctors need to be sensitive to patients’ preferences for involvement in the decision-making process and for the way
information on risk is shared. Providing written information specific to the individual patient is likely to facilitate shared decisions about
preventive medication.
Keywords: patient participation; patient-centred care; primary prevention; risk; decision-making
INTRODUCTION
The aim of long-term preventive medication is to reduce
the risk of illness, rather than hoping, against the odds,
that the individual patient will necessarily benefit.
1
We
know from previous research that only about one-
quarter of people would take a drug offering 5% absolute
risk reduction over five years.
2
This was despite their
being told that the hypothetical treatment was safe.
“With heart disease, study after study has shown that
patients are nowhere as enthused about all this medication
as their doctors are for prescribing it, with discontinuation
rates of lipid-lowering therapy up to 50% after one year and
85% after two years. So, the fact that we can offer prevention
isn’t as simple as it seems.” (David Haslam, The James
Mackenzie Lecture 2006.
3
)
Some medical professionals suggest that one-third of
people over the age of 55 could benefit from taking a
polypill of preventive medication,
4
but a substantial
proportion of the public is giving a completely different
message
5
by taking the decision to stop recommended
drugs.
6,7
Resolving this issue is crucial if we are to target
resources where they are most useful
8
because, without
acceptance from the patient, medication will be wasted
or taken too erratically, or for too short a time, to reap
any benefit.
9,10,11
Alongside these pragmatic concerns, it is
unethical to mislead patients into taking medication in
the erroneous belief that it is bound to be good for
them.
12,13,14
This study aimed to explore patients’ perceptions of
preventive medication, to see if there is a desire for
information that would enable an informed choice, and,
if so, what form this information should take.
METHODS 
A focus group discussion guide was developed by the lead
researcher and then tested by a pilot focus group.
Bedfordshire Local Research Ethics Committee approval
was granted for the study. The nurse at each of the two
participating practices recruited participants, who were
invited by letter or opportunistically. 
Participants had an initial meeting with the nurse to
discuss the study aims, with examples of some formats
used for providing medical information, including: a
graphic document using smiley faces, an audio compact
disc, a patient drug information leaflet, an extract from
the Summary of Product Characteristics for a preventive
drug for bone loss listing the benefits and frequency of
side-effects, and a text document giving an individual’s
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10-year risk of a heart attack related to lifestyle factors, blood pressure
and cholesterol level plus a summary of side-effects of some
antihypertensive drugs in common use. The style of the text document
was similar to one suggested by Pignone,
15 
providing data specific to the
individual patient followed by absolute risk, expressed as a percentage
and approximation in integers (eg one in five) of an event within 10
years and what would happen to this figure if a risk factor changed,
such as giving up smoking.
In February and March 2007, four focus groups each lasting two
hours were held in two general practices in Letchworth and Luton. The
groups were run by an independent researcher acting as moderator,
and a medical health professional taking notes. Box 1 gives the outline
discussion structure and Box 2 the example presentation styles. The
discussions were recorded and transcribed.  Refreshments and travel
expenses were provided.
Following the constant comparative method, thematic analysis was
an iterative process using techniques from a grounded theoretical
approach,
16
with categories emerging after systematic analysis of the
textual discussion.  Initially, manual coding was used and this began
with initial familiarisation with the data. The coding was then entered
into the computer package QSR NUD*IST (N6). This ordering of data
facilitated the later identification of emerging issues raised by
participants, identified recurrent patterns, and permitted comparisons
with concepts present in the literature.
Participants
Purposive sampling was used to select patients from the computer
registers of each practice who were likely to have a specific interest in
preventive medication. 
Inclusion criteria
• 18 years or older
• able to contribute to a focus group discussion in English
• able to attend the meeting venue
• people with a personal risk factor such as high blood pressure,
hypercholesterolaemia, or diabetes, or
• people who have had a primary event such as a heart attack or
stroke, or
• a relative of someone so affected, or
• someone who has experienced an adverse drug reaction from
preventive medication
A spreadsheet was used to maximise the diversity within each group.
The aim of this was not to attempt any subgroup analysis (the number of
participants in any one category would be small) but to facilitate a broad
range of opinion to be expressed in the focus group discussions. The
commonest preventive medication being taken was an antihypertensive
or a statin, or both. Some patients had been taking preventive
medication for only a few months and others as long as 30 years.
RESULTS
Study participants
Table 1 gives details of the participants. In total, 28 individuals took part
in the study: 15 female and 13 male. All were resident in the UK; two
were of Asian origin and one from Poland. The ages of the groups ranged
from 46 to 90 years. Health deprivation scores were derived from
Neighbourhood Statistics
17
using the practice postcodes,
18
with most
patients from each practice living within one postcode area. The sample
was a stable population who had lived in the area for many years. In
addition to the 28, four people declined the invitation because of the
time of the afternoon meetings, and four accepted but did not attend.
Table 1. Demographic data for the focus group participants
Focus Age Mean Sex Location Health Health
Group Range Age Deprivation Deprivation
(Yrs) (Yrs) Index* Rank*
M F (centile)
FG1 56-90 70.6 5 3 Letchworth -1.01 28,164 (87)
FG2 65-79 73.0 2 3 Letchworth -1.01 28,164 (87)
FG3 56-77 69.1 4 4 Luton -0.69 25,066 (77)
FG4 46-67 59.0 2 5 Luton -0.69 25,066 (77)
All 46-90 67.7 13 15
* UK Government Indices of Deprivation 2007 for Super Output Areas, rank 1 being the
most deprived, rank 32,482 the least.
Box 1. Outline of part of the discussion structure
What information is required about the benefit
to the individual patient?
to the patient as a member of a special risk group?
to the patient as a member of the population?
What information is required about the disadvantages
to the individual patient?
to everyone who takes the medication?
to everyone who takes any medication?
Box 2. Presentation styles
How should the information be presented to patients? 
A variety of ways of presenting information can be used as examples for the
group to consider, while leaving it open for the group to suggest an entirely
new way to convey the information.
Example presentation formats: information sheets in text or graphics or both,
audio cassette, video, one-to-one discussion with doctor or nurse.
Numerical / non-numerical.
Primarily text / graphics.
Chance or risk, number needed to treat / number needed to harm.
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Table 2 shows the frequency of the clinical inclusion criteria for the
four groups, with some participants fulfilling more than one criterion
as a major reason for being invited.
Information on starting preventive medication
The majority of focus group participants who had been prescribed a
preventive medication said that they had received very little or no
information about benefits and possible disadvantages when it was
started.
“I’ve been to see other doctors, they just write me out a
prescription and say ‘take this.” [FG3]**
“He [the doctor] just said, ‘you know, it’s going up and it won’t
come down and you’d be well advised,’ he said ‘you don’t have
to, but you’d be well advised to start taking blood pressure
tablets.” [FG2]
** The quotes provided are from a range of individuals (males and females) in the sample.
[FG] indicates the discussion group. Examples were given of some
recent consultations in which general practitioners (GPs) were
providing more explanation, which was appreciated by participants.
“The doctor don’t rush you … no Dr X doesn’t, no.
He writes it all down and gives you a copy, well I’ve got a copy,
explains everything, you know.” [FG3]
Perceived benefits of preventive medication
There was some underlying scepticism from many participants about
the statistics used to portray risk, in that they were either too
complicated or simply irrelevant to them.
“You can look on the Internet and you would see waves and
swathes of statistics in all of this. Who do you believe, how do
you believe?” [FG1]
“I would have thought that if some form of medication is
going to reduce the risk by whatever percentage it is, then it’s
worth taking it.” [FG1]
The fourth focus group, of younger participants, was more positive
about information containing percentages. Five of the seven participants
in this younger group said they wanted more information about their
own personal risk of heart attack. Some wanted to monitor the effect of
their medication on their risk.
“But if you knew your percentage risk and you knew that that
changed over … like if you were taking them and two years
later you see your percentage has gone down or gone up, then
you can think around that a bit more can’t you?” [FG4]
The majority of participants were not interested in statements about
people who were similar to them, but only those that related to them
personally.
“I’m not interested in anybody similar to me, I’m interested in
me!” [FG3]
“But as you say it’s personal to you, a person asking your
particular situation is what you want isn’t it really?” [FG4]
Only two of the 28 participants had received a personal risk
assessment of their chance of having a heart attack. One participant
said they had not realised it was possible to calculate an individual risk.
A few participants acknowledged the difficulty of applying population
data to the individual.
“You have to weigh up what that statistic means to you: 
1 in 5 are you going to be the 1 in 5?” [FG4]
Participants were somewhat reluctant to identify what they
themselves felt to be the benefits, and, instead, reported what their
doctor had told them. A few said they felt healthier while taking the
medication, but most said they noticed no difference to their health.
“When I was first diagnosed with it I didn’t feel poorly and I
don’t feel poorly now.” [FG4]
Only a few of the younger participants who monitored their blood
pressure felt they had evidence of benefit.
“I mean the tablets dragged it [blood pressure] down with me,
they’ve kept it down, there’s no doubt about that, they do
work.” [FG4]
Perceived disadvantages of preventive medicine
Some participants denied side-effects, others did not recognise them,
and some “put up” with them. It was noted that it could be difficult to
attribute side-effects to a medication. Some people returned to their
doctor asking for a change of tablets, while others felt that side-effects
took time to “settle down”.
“I could live quite happily without knowing about side-effects
because I could turn that round and attribute them to it. I’m
going to stop taking that because my feet are warm.
(Laughter)” [FG1]
“If you do get nasty side-effects, is it just a passing thing that
your system will settle down and then they’ll go?” [FG1]
Some participants believed the effect of their tablets would diminish
over time, so they should be changed after a certain period, or because
there would be a newer, better alternative.
Table 2. Frequency of inclusion criteria
Focus Group
Inclusion Criteria 1 2 3 4 Total
Personal risk factor 8 5 6 7 26
Primary event 4 1 3 1 9
Relative with risk factor 1 0 1 1 3
or primary event
Personal experience 3 2 4 5 14
of side-effects
Total 16 8 14 14
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“I think when you’ve been on a tablet a very long time I think
your system gets used to it so it doesn’t have any effect on it, you
know after a long time, it doesn’t help you as it should do.” [FG4]
It was felt that the anxiety from reading about possible adverse
reactions might be harmful, especially to someone with high blood
pressure, and that a list of “frightening” side-effects could stop people
taking necessary medication, or generate side-effects by suggestion.
“I think too much information is worrying.” [FG1]
“I say ‘no don’t tell me what the side-effects are’.” [FG1]
Information style
Of the example materials, the text document giving an individual’s 10-
year risk of a heart attack was the style that most people welcomed.
Information on frequencies of side-effects was perceived as being too
technical. The patient information leaflet fared little better because of
its small print, technical language and similarity with other leaflets. 
“And you tend then to just read a few lines and then, oh I can’t
be bothered with that, I can’t see or get a magnifying glass
out.” [FG4]
“But I notice on a lot of these side-effects, when they say …
nearly every leaflet is the same isn’t it? You know they say
exactly the same things, whatever it is you’re taking.” [FG4]
The graphic with smiley faces received a mixed reception, with some
liking its style while others thought it childish.
“I think that’s a good idea, that diagram. Happy little faces
and unhappy little faces.” [FG2]
“It’s short and to the point.” [FG2]
“It looks very childish to me.” [FG2]
Graphics were seen as a good way to improve the presentation of
numerical information, but graphs were not.
“Information is always easier to receive visually.” [FG4]
“It’s like all the graphs … you couldn’t prove anything …”
[FG1]
When participants referred to a numerical risk, they expressed this
using numbers under 100, such as ‘1 in 10’. Larger numbers were seen
as expressing remote risks and, as such, were lumped together as
indicating that rare things occasionally happen, which was seen as
inevitable anyway.
“…I would sort of almost dismiss it because it’s only very
occasional, you’re 1 in 1000 …” [FG1]
“I think on a personal level I’d just like to know there’s a
chance that 1 in every 100 people who take the medication
develop a wheeze so I know if I develop a wheeze I’ll do
something about it” [FG4]
The audio compact disc was criticised for being difficult to refer back
to in order to clarify points later.
“Sometimes you can’t always remember everything that’s
been said anyway and having it written down …” [FG2]
The decision to treat or not
The majority of participants, particularly the older ones, expected their
GP to suggest medication only when it was necessary. Choice was
thought to be over-rated.
“I would like more information but not the full medical
details because I don’t understand it. Choices are very
over-rated, I mean we are not statisticians.” [FG1]
If they were to be involved, they would want to compare themselves
with the “norm”. Participants saw this as quite different from population
data. One participant wanted such information so that she could adapt
her lifestyle as well as, or instead of, taking preventive medication.
“If they gave us the norm, if there is such a thing for a
person of my age and my weight and all the rest …
perhaps then I could look at that and see where I am in the
norm” [FG1]
Focus group 4 (with the youngest mean age) showed the most
interest in personal risk and also demonstrated knowledge of personal
blood pressure and cholesterol readings. It was suggested that patients
could have access to their own medical records via the Internet,
including a graph showing their data over time, and links to web sites
where help with interpretation could be found.
Choice of drug
Focus group 4 suggested they might help in the selection of their own
medication if provided with the contraindications and possible adverse
effects of a list of drugs.
“So you can actually look and say well why can’t I go on that
one?” [FG4]
Although these participants wanted to be more involved they
recognised that it was not always easy to know what to ask.
“If you ask, you get information, if you ask the question – but
it’s knowing the right question to ask” [FG4]
DISCUSSION
Summary of main findings
The majority of participants in this small study, particularly the older
ones, thought they had little role in the decision to start preventive
medication. They trusted their doctor and would take whatever
medication they were given. They felt that any reduction in risk was
worth having, without balancing this against possible disadvantages. 
Younger participants wanted to be actively involved in decision-
making, and some wanted interactive access to their own records, with
ongoing feedback of the effects of medication on both their medical
condition and their risk. 
Personalised information was welcome, paradoxically even by those
who expressed little interest in choice. Population data were dismissed
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as either irrelevant or too complex. The concept of an individual with
the same risk factors was not considered an attractive way to impart
information. What the participants wanted was their own, individual
risk explained by comparison with the “norm”. When numbers are used
to explain risk, keeping them smaller than 100 helps people understand
how the risk applies to them. 
Many participants were not particularly interested in knowing about
the disadvantages of medication. The more prominent concern was
about the anxiety that can be caused by lists of side-effects, with
suggestions of extreme ways to avoid this, such as denial that they
existed or avoidance of reading the patient information leaflet altogether. 
The response to example materials was to focus on the potential
benefits to the individual and largely ignore information about
disadvantages. This may be partly because relatively few people
experience serious side-effects and minor ones can always be put down
to something else. Graphics were welcomed, but not line graphs.
Strengths and limitations of the study
The major limitation of the study is the small number of participants,
which makes the findings difficult to generalise. However, a great deal
of information was obtained from each participant, adding to the depth
of the findings. Qualitative research using analysis of focus group
discussions can elucidate the reasons for perceptions and patterns of
behaviour, and we have taken care not to de-contextualise words,
which may misrepresent the meaning.
Participants gave their time freely and had no particular bias for or
against medication, although it is possible that those who felt less
favourable to the use of medication would be less likely to participate. 
The two general practices involved are not typical of the country as a
whole, although the focus groups covered a range of ages and
demographic factors. The focus groups were held in the afternoon,
biasing the participants towards people without a full-time occupation
and towards those who had retired.
Comparison with existing literature
Although patient-centred consultations are welcomed by patients,
19
patient choice is no guarantee of a good outcome,
20
and patients have a
preference for being involved in major decisions more than minor
ones.
21
Other studies have found that patients often do not wish to be
involved,
22
with 69% of people in an American study preferring to leave
medical decisions to their doctors, and that the wish to be involved
decreased with age and increased with education.
23
A study of patients’ preferences carried out in South London found
that 45% of patients wanted their GP to be the main or only decision-
maker; 39% wanted the GP to share the decision and 16% wanted to be
the main or only decision-maker.
24
It was also found that GPs’
perceptions of their patients’ ‘desire to be involved in decisions’ were
inaccurate two-thirds of the time. Our study supports these findings in
that it was apparent that there was less interest in being involved in
decision-making from many older participants. 
Telling people about adverse effects may not change their use of
medication,
25
but a 2006 national survey of patients’ experience in
England found that 42% of respondents said they would like more
information about side-effects.
26
Our  study suggests that doctors need
to be sensitive to patients’ preferences about the communication of
side-effects. 
Doctors have difficulty in communicating information about risk to
patients,
27,28,29,30,31
and yet such information is important to enable
informed decisions.
32,33
It is clear from this study that many patients find
the statistics used to convey risk unhelpful and confusing. The format
of data presentation is known to affect patients’ decisions.
34,35
One way
around the dislike of large numbers is to use a standardised language of
risk, as suggested by Calman in 1996.
36
Another is to use graphics.
Pictures can be seen as helpful,
37,38,39,40
but decision aids using graphs
have not been widely adopted.
41,42
In this study text and graphics (but
not graphs) were preferred to audio because they are easier to refer back
to later for clarification.
Implications for future research or clinical practice
Historically, doctors have often not involved patients in the decision to
start preventive medication. Participation is now expected, particularly
by younger patients, but doctors need to remain sensitive to patient
preferences for involvement in the decision-making. When patients
want to be involved, the most helpful method of providing information
is to individualise it. A comparable hypothetical person, or a population
of such people is not felt to be helpful, but confusing.  Text and graphics
(but not graphs) were preferred to audio because they are easier to refer
back to later for clarification. Future research could test the
recommendations from this study by examining patients’ responses to
information given when they are offered preventive medication.
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